Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study

Table 3 Association of apolipoprotein A-IV with incident cancer during the prospective follow-up in patients without a history of cancer at the baseline investigation (4424 out of 5039 patients) ^a

		HR	95% CI	p-value
Calculations for median of apoA-IV concentrations^b
Model 1: 368 cases (174 above and 194 below median)^c		0.73	0.58–0.91	0.006
Model 2: 362 cases (171 above and 191 below median)^c		0.72	0.57–0.90	0.004
Calculations per quartile of ApoA-IV concentrations
Model 1	Quartile 1 (90 cases)^c	1.00
	Quartile 2 (104 cases)^c	1.00	0.75–1.33	0.98
	Quartile 3 (85 cases)^c	0.73	0.54–0.99	0.04
	Quartile 4 (89 cases)^c	0.74	0.53–1.02	0.07
Model 2	Quartile 1 (88 cases)^c	1.00
	Quartile 2 (103 cases)^c	1.02	0.76–1.36	0.91
	Quartile 3 (83 cases)^c	0.72	0.53–0.98	0.04
	Quartile 4 (88 cases)^c	0.73	0.53–1.02	0.07

Model 1: adjusted for age, sex, ln-urine albumin-creatinine ratio and eGFR_cystatin-C
Model 2: as model 1 plus statin use, smoking, BMI, diabetes
Abbreviations: HR hazard ratio, CI confidence interval
^aPatients with a history of cancer at the time of enrollment were not considered in this analysis
^bReference category includes apoA-IV values below median. The median apoA-IV concentration is 27.6 mg/dL (referring to the total group of 5039 patients)
^c“Cases” refers to the number of patients with incident cancer events. Differences in number of cases between model 1 and 2 are explained by patients with few missing covariates for model 2

ISSN: 1471-2407